Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Chemmedchem|July 24, 2023
Back in Person: Frontiers in Medicinal Chemistry 2023Matthias Gehringer, Felix Pape, María Méndez, et al.Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.Journal of Medicinal Chemistry|December 21, 2019
Discovery of BAY-985, a Highly Selective TBK1/IKKε InhibitorJulien Lefranc, Volker Klaus Schulze, Roman Christian Hillig, et al.Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.Chemmedchem|June 17, 2016
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)William J Scott, Martin F Hentemann, R Bruce Rowley, et al.Journal for Immunotherapy of Cancer|November 14, 2023
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapyChristina Kober, Julian Roewe, Norbert Schmees, et al.Nucleic Acids Research|December 8, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapyEeson Rajendra, Claudio A Lademann, Bethany Mason, et al.Journal of Medicinal Chemistry|December 8, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1Sam E Mann, Owen A Davis, Jörg Bomke, et al.Journal of Medicinal Chemistry|September 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 InhibitorSam E Mann, Julien Lefranc, Omar Alkhatib, et al.Pageof 2